Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma

Trial Profile

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Vorinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 29 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 19 Oct 2010 Planned end date changed from Apr 2012 to Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top